The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Clinical pharmacology and therapy

• Publication date

  1991-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.1991.4PMID 1988236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sparteine oxidation polymorphism in Denmark.

  2009cited by this paper
• Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

  2004cited by this paper
• Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

  2004cited by this paper
• Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics

  2004cited by this paper
• Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

  2004cited by this paper
• Clinical significance of the sparteine/debrisoquine oxidation polymorphism

  2004cited by this paper
• Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

  1989cited by this paper
• Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

  1989cited by this paper
• Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype

  1989cited by this paper
• Therapeutic drug monitoring of tricyclic antidepressants: a means of avoiding toxicity.

  1989cited by this paper
• S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin

  1989cited by this paper
• First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

  1988cited by this paper
• Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype

  1986cited by this paper
• Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

  1985cited by this paper
• Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

  1985cited by this paper
• Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

  1985cited by this paper
• Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes

  1984cited by this paper
• Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism

  1984cited by this paper
• Clinical Pharmacokinetics: Concepts and applications.

  1983cited by this paper
• Imipramine metabolites in blood of patients during therapy and after overdose

  1983cited by this paper
• The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

  1983cited by this paper
• Interindividual differences in amitriptyline demethylation

  1980cited by this paper
• Food, splanchnic blood flow, and bioavailability of drugs subject to first‐pass metabolism

  1978cited by this paper
• Clinical implications of imipramine plasma levels for depressive illness.

  1977cited by this paper
• Steady-state kinetics of imipramine in patients

  1977cited by this paper
• Imipramine: Clinical effects and pharmacokinetic variability

  1977cited by this paper
• Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man

  1976cited by this paper
• Intestinal absorption, demethylation, and enterohepatic circulation of imipramine

  1976cited by this paper
• First‐pass metabolism of imipramine in man

  1975cited by this paper
• Metabolism of tricyclic antidepressants. A review.

  1974cited by this paper

• Analysis of blood-brain barrier permeability of drugs using forensically obtained human cerebrospinal fluid and plasma in Japan.

  2025cites this paper
• In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach.

  2025cites this paper
• Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants

  2022cites this paper
• Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes

  2022cites this paper
• Prediction of Metabolite‐to‐Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model

  2019cites this paper
• P450 Pharmacogenetics in Indigenous North American Populations

  2018cites this paper
• Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects

  2017cites this paper
• The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine

  2016cites this paper
• Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland

  2015cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine

  2013cites this paper
• Methylphenidate and Its Underrecognized , Under-explained , and Serious Drug Interactions : A Review of the Literature with Heightened Concerns

  2013cites this paper
• Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• Tricyclic Antidepressant Drug Interactions

  2012cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Species Differences of Drug‐Metabolizing Enzymes

  2011cites this paper
• A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer

  2010cites this paper
• SNPs: Single Nucleotide Polymorphisms and Pharmacogenomics: Individually Designed Drug Therapy

  2010cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Sex-specific differences in CYP450 isoforms in humans

  2008cites this paper
• Pharmacogenetics: part II: Perspective. 1992.

  2007cites this paper
• Pharmacogenetics: Part II

  2007cites this paper
• Single nucleotide polymorphisms of CYP2C19 gene and AHR gene and their associations to colorectal cancer and breast cancer risk in Han Chinese population

  2007cites this paper
• Species and strain differences in drug metabolism in liver and intestine

  2006cites this paper
• Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

  2006cites this paper
• Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations

  2006cites this paper
• Species and strain differences in drug metabolism in liver and intestine

  2006cites this paper
• Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation

  2006cites this paper
• Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

  2006cites this paper
• Species and strain differences in drug metabolism in liver and intestine

  2006cites this paper
• Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s.

  2005cites this paper
• Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism

  2005cites this paper
• Pharmacogenetics of Antidepressant Drug Metabolism and Its Clinical Implications

  2005cites this paper
• In vitro microsomal metabolism of imipramine under conditions mimicking the in vivo steady‐state situation

  2004cites this paper
• Monoamine Oxidase Inhibitors and Tricyclic Antidepressants

  2004cites this paper
• Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study

  2004cites this paper
• Some aspects of genetic polymorphism in the biotransformation of antidepressants.

  2004cites this paper
• Drug-Metabolizing Enzymes and P-Glycoprotein

  2004cites this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cites this paper
• Contribution of human cytochrome P‐450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine

  2003cites this paper
• Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.

  2003cites this paper
• Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence

  2003cites this paper
• Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.

  2003cites this paper
• Individualized Medicine - Implementation of Pharmacogenetic Diagnostics in Antidepressant Drug Treatment of Major Depressive Disorders

  2003cites this paper
• Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A.

  2003cites this paper
• Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

  2002cites this paper
• The N-Demethylation of the Doxepin Isomers Is Mainly Catalyzed by the Polymorphic CYP2C19

  2002cites this paper
• Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

  2002cites this paper
• Effect of Fluoxetine and Imipramine on the Pharmacokinetics and Tolerability of the Antipsychotic Quetiapine

  2002cites this paper
• Clinical implications of CYP2C19 polymorphism for tailor-made pharmacotherapy

  2002cites this paper
• The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

  2002cites this paper
• Pharmacokinetic and Pharmacodynamic Drug Interactions in the Treatment of Attention-Deficit Hyperactivity Disorder

  2001cites this paper
• Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

  2001cites this paper
• Human Cytochromes P450 and Their Role in Metabolism-Based Drug-Drug Interactions

  2001cites this paper
• In Vivo Probes for Studying Induction and Inhibition of Cytochrome P450 Enzymes in Humans

  2001cites this paper
• CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

  2001cites this paper
• Development of a semi-quantitative assay to detect full-length CYP2C19 RNA.

  2000cites this paper
• Effect of venlafaxine on imipramine metabolism.

  2000cites this paper
• The CYP2C19 Enzyme Polymorphism

  2000cites this paper
• Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.

  2000cites this paper
• THE INFLUENCE OF ETHNICITY AND ANTIDEPRESSANT PHARMACOGENETICS IN THE TREATMENT OF DEPRESSION

  2000cites this paper
• The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat.

  1999cites this paper
• Metabolism of Tricyclic Antidepressants

  1999cites this paper
• Imipramine for Cytochrome P450 Activity Determination: a Multiple-species Metabolic Probe.

  1999cites this paper
• Lipoxygenase-Mediated N-Demethylation of Imipramine and Related Tricyclic Antidepressants in the Presence of Hydrogen Peroxide

  1999cites this paper
• A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

  1999cites this paper
• Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.

  1999cites this paper
• The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics

  1998cites this paper
• An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

  1998cites this paper
• Die Bedeutung des hepatischen Cytochrom-P450-Systems für die Psychopharmakologie

  1998cites this paper
• A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

  1998cites this paper
• Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

  1998cites this paper
• Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype

  1998cites this paper
• Human cytochrome P450s: selectivity and measurement in vivo.

  1998cites this paper
• Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism

  1998cites this paper
• [Significance of hepatic cytochrome P450 enzymes for psychopharmacology].

  1998cites this paper
• A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry.

  1998cites this paper
• Relationship between Phenotype and Genotype of CYP2C19 Using a Simplified Method for Phenotyping with Omeprazole in Healthy Japanese

  1998cites this paper
• Pharmacogenetics of the hepatic cytochrome P450 enzyme system: its relevance for prescribing in psychiatry

  1998cites this paper
• The Role of Metabolites of Antidepressants in the Treatment of Depression

  1997cites this paper
• Drug Interactions of Clinical Significance with Selective Serotonin Reuptake Inhibitors

  1997cites this paper
• Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.

  1997cites this paper
• Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.

  1997cites this paper
• Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs.

  1997cites this paper
• The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition.

  1997cites this paper
• Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

  1997cites this paper
• OF CLOZAPINE BY cDNA-EXPRESSED HUMAN CYTOCHROME P 450 ENZYMES

  1997cites this paper
• Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4

  1997cites this paper
• Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.

  1997cites this paper
• Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.

  1997cites this paper
• Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy

  1997cites this paper
• Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms.

  1997cites this paper
• Pharmacogenetics of antidepressants: clinical aspects

  1997cites this paper
• S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.

  1996cites this paper
• Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.

  1996cites this paper
• Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

  1996cites this paper
• Formation of meprobamate from carisoprodol is catalysed by CYP2C19.

  1996cites this paper
• Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.

  1996cites this paper